课题基金 / 基金详情

MKC 442--TRIPLE DRUG COMBINATION IN PATIENTS W/ HIV

MKC 442--TRIPLE DRUG COMBINATION IN PATIENTS W/ HIV
MKC 442——艾滋病毒患者的三联药物
批准号：
6264678
负责人：
Martin H Markowitz
金额：
$4.54万
依托单位：
ROCKEFELLER UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264678
关键词：
AIDS therapy HIV infections antiAIDS agent clinical research combination chemotherapy human subject human therapy evaluation protease inhibitor reverse transcriptase inhibitors

项目摘要

项目成果

Martin H Markowitz的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Protocol title: An Open Label Study of MKC-422 in at Least Triple Drug Combination in patients Previously Treated with Nucleoside Reverse Transcriptase and Protease Inhibitors and Who are Naive to Non-Nucleoside Reverse Transcriptase Inhibitors Primary objectives: 1. To determine the proportion of patients whose plasma HIV-1 RNA level remains below the limit of quantification of the Roche Apmlicor assay (400 copies/ml) at each time point and at 24 weeks. 2. To determine the short term safety and tolerability of MKC-442 in combination with other antiretrovirals. 3. To determine the time to virologic failure.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
A preclinical assessment of monthly intramuscular GSK1265744, an InSTI, as PrEP
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs
Correlates and Consequences of Increased Immune Activation in HIV + and - IDUs
海外基金